Hong Kong Stock Movers: CRO Concept Stocks Continue Climbing; WuXi Apptec Legal Progress Could Boost CXO Companies' Overseas Contract Wins

Stock News08-11

CRO concept stocks continue their upward trend in Hong Kong trading. As of the latest press time, Pharmaron (03759) surged 9.61% to HKD 30.10, while Genscript Bio (01548) rose 8.44% to HKD 26.20. Asymchem (06821) gained 4.83% to HKD 130.30, and WuXi Apptec (02359) advanced 2.22% to HKD 202.40.

The CRO sector has recently been buoyed by multiple positive developments. The U.S. July non-farm payrolls report showed a decline of 23,000 jobs, significantly missing the market expectation of an 80,000 increase. In legal news, WuXi Apptec has achieved a delay in the enforcement of the U.S. Department of Defense's 1260H designation against the company. Several pharmaceutical industry leaders, including WuXi Apptec and BeiGene, have reported strong mid-year revenue growth.

Guoyuan International noted that the probability of a U.S. interest rate hike has decreased, overseas financing conditions have fully recovered, and external demand has improved markedly. The legal progress for WuXi Apptec is favorable for CXO companies seeking new contracts abroad. The consistent outperformance of Chinese innovative drugs going global has fully validated the global competitiveness of China's innovative drug assets. The firm holds a strong bullish outlook on the innovative drug supply chain sector, recommending attention to companies with globally competitive pipelines and substantial business development deals either completed or anticipated, as well as CXO firms demonstrating rapid earnings growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191529182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191529182","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Movers: CRO Concept Stocks Continue Climbing; WuXi Apptec Legal Progress Could Boost CXO Companies' Overseas Contract Wins","media":"Stock News","content":"<p>CRO concept stocks continue their upward trend in Hong Kong trading. As of the latest press time, <b>Pharmaron</b> (<b>03759</b>) surged 9.61% to HKD 30.10, while <b>Genscript Bio</b> (<b>01548</b>) rose 8.44% to HKD 26.20. <b>Asymchem</b> (<b>06821</b>) gained 4.83% to HKD 130.30, and <b>WuXi Apptec</b> (<b>02359</b>) advanced 2.22% to HKD 202.40.<br><br>The CRO sector has recently been buoyed by multiple positive developments. The U.S. July non-farm payrolls report showed a decline of 23,000 jobs, significantly missing the market expectation of an 80,000 increase. In legal news, <b>WuXi Apptec</b> has achieved a delay in the enforcement of the U.S. Department of Defense's 1260H designation against the company. Several pharmaceutical industry leaders, including <b>WuXi Apptec</b> and <b>BeiGene</b>, have reported strong mid-year revenue growth.<br><br>Guoyuan International noted that the probability of a U.S. interest rate hike has decreased, overseas financing conditions have fully recovered, and external demand has improved markedly. The legal progress for <b>WuXi Apptec</b> is favorable for CXO companies seeking new contracts abroad. The consistent outperformance of Chinese innovative drugs going global has fully validated the global competitiveness of China's innovative drug assets. The firm holds a strong bullish outlook on the innovative drug supply chain sector, recommending attention to companies with globally competitive pipelines and substantial business development deals either completed or anticipated, as well as CXO firms demonstrating rapid earnings growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movers: CRO Concept Stocks Continue Climbing; WuXi Apptec Legal Progress Could Boost CXO Companies' Overseas Contract Wins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movers: CRO Concept Stocks Continue Climbing; WuXi Apptec Legal Progress Could Boost CXO Companies' Overseas Contract Wins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-11 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CRO concept stocks continue their upward trend in Hong Kong trading. As of the latest press time, <b>Pharmaron</b> (<b>03759</b>) surged 9.61% to HKD 30.10, while <b>Genscript Bio</b> (<b>01548</b>) rose 8.44% to HKD 26.20. <b>Asymchem</b> (<b>06821</b>) gained 4.83% to HKD 130.30, and <b>WuXi Apptec</b> (<b>02359</b>) advanced 2.22% to HKD 202.40.<br><br>The CRO sector has recently been buoyed by multiple positive developments. The U.S. July non-farm payrolls report showed a decline of 23,000 jobs, significantly missing the market expectation of an 80,000 increase. In legal news, <b>WuXi Apptec</b> has achieved a delay in the enforcement of the U.S. Department of Defense's 1260H designation against the company. Several pharmaceutical industry leaders, including <b>WuXi Apptec</b> and <b>BeiGene</b>, have reported strong mid-year revenue growth.<br><br>Guoyuan International noted that the probability of a U.S. interest rate hike has decreased, overseas financing conditions have fully recovered, and external demand has improved markedly. The legal progress for <b>WuXi Apptec</b> is favorable for CXO companies seeking new contracts abroad. The consistent outperformance of Chinese innovative drugs going global has fully validated the global competitiveness of China's innovative drug assets. The firm holds a strong bullish outlook on the innovative drug supply chain sector, recommending attention to companies with globally competitive pipelines and substantial business development deals either completed or anticipated, as well as CXO firms demonstrating rapid earnings growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1191529182","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191529182","pubTimestamp":1786420222,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CRO concept stocks continue their upward trend in Hong Kong trading. As of the latest press time, Pharmaron (03759) surged 9.61% to HKD 30.10, while Genscript Bio (01548) rose 8.44% to HKD 26.20....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","03759":"康龙化成","LU0611395673.USD":"NINETY ONE GSF EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4588":"碎股","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1576":"医药外包概念","02359":"药明康德","BK1141":"生命科学工具和服务","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","VXUS":"国际股票ETF-Vanguard","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","06127":"昭衍新药","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4585":"ETF&股票定投概念","01548":"金斯瑞生物科技","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0700851271.USD":"NINETY ONE GSF EMERGING MARKETS MULTI-ASSET \"A\" (USD) ACC","CXO":"康休","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","WX":"Corgi All World 2x Daily ETF","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK0216":"研究试验","KCAI":"KraneShares China Alpha Index ETF","BK1583":"高瓴概念","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD"},"translate_title":"港股风云人物：CRO概念股持续攀升；药明康德法律进展可能会促进 CXO 公司赢得海外合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"CXO":1,"WX":1,"02359":1,"03759":1,"VXUS":1,"KCAI":1,"01548":1,"06127":1},"content_text":"CRO concept stocks continue their upward trend in Hong Kong trading. As of the latest press time, Pharmaron (03759) surged 9.61% to HKD 30.10, while Genscript Bio (01548) rose 8.44% to HKD 26.20. Asymchem (06821) gained 4.83% to HKD 130.30, and WuXi Apptec (02359) advanced 2.22% to HKD 202.40.The CRO sector has recently been buoyed by multiple positive developments. The U.S. July non-farm payrolls report showed a decline of 23,000 jobs, significantly missing the market expectation of an 80,000 increase. In legal news, WuXi Apptec has achieved a delay in the enforcement of the U.S. Department of Defense's 1260H designation against the company. Several pharmaceutical industry leaders, including WuXi Apptec and BeiGene, have reported strong mid-year revenue growth.Guoyuan International noted that the probability of a U.S. interest rate hike has decreased, overseas financing conditions have fully recovered, and external demand has improved markedly. The legal progress for WuXi Apptec is favorable for CXO companies seeking new contracts abroad. The consistent outperformance of Chinese innovative drugs going global has fully validated the global competitiveness of China's innovative drug assets. The firm holds a strong bullish outlook on the innovative drug supply chain sector, recommending attention to companies with globally competitive pipelines and substantial business development deals either completed or anticipated, as well as CXO firms demonstrating rapid earnings growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191529182","isCrawlerRequest":true}